Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.55% | 22.30% | -10.21% | -36.89% | -30.00% |
| Depreciation & Amortization | -26.67% | -25.00% | -23.53% | -26.32% | -28.57% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.42% | 22.22% | -10.24% | -36.87% | -29.99% |
| Operating Income | -53.42% | -22.22% | 10.24% | 36.87% | 29.99% |
| Income Before Tax | -56.70% | -20.45% | 10.59% | 35.54% | 28.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.70% | -20.45% | 10.59% | 35.54% | 28.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.70% | -20.45% | 10.59% | 35.54% | 28.50% |
| EBIT | -53.42% | -22.22% | 10.24% | 36.87% | 29.99% |
| EBITDA | -53.55% | -22.30% | 9.82% | 36.66% | 29.74% |
| EPS Basic | -44.74% | -13.75% | 18.63% | 42.74% | 39.68% |
| Normalized Basic EPS | -46.81% | -18.37% | 21.54% | 43.59% | 40.51% |
| EPS Diluted | -44.74% | -13.75% | 18.63% | 42.74% | 39.68% |
| Normalized Diluted EPS | -46.81% | -18.37% | 21.54% | 43.59% | 40.51% |
| Average Basic Shares Outstanding | 7.99% | 5.48% | 8.57% | 11.26% | 17.44% |
| Average Diluted Shares Outstanding | 7.99% | 5.48% | 8.57% | 11.26% | 17.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |